Modulatory effect of Origanum majorana extract against cisplatin-induced dyslipidemia in rats

Shreen Desouky, Mohamed Marzouk, Amel M. Soliman and Amany A. Sayed

Cisplatin (CDDP) drug is one of the platinum compounds that used for the treatment of a variety of human neoplasms. However, its high doses produce undesirable toxic side effects. Origanum majorana is a natural herbal product used in the management of many diseases. Therefore, the present study investigated the curative effect of Origanum majorana ethanolic extract (OMEE) on the lipid profile abnormalities induced by cisplatin. Male Wistar rats were randomly separated into four groups (n=6). Rats in group 1 act as controls and received distilled water orally for 14 days. Rats of groups 2, 3 and 4 injected a single dose of CDDP (3 mg/kg body weight, i.p); then after 3 days of CDDP injection, rats were challenged with distilled water, OMEE (500 mg/kg body weight), and silymarin (150 mg/kg/ body weight); respectively orally for 14 consecutive days. The present study revealed that CDDP caused body, liver and kidney weights loss within the experimental period. Moreover, CDDP increase the serum total lipid, triglycerides and LDL-cholesterol levels significantly. Conversely, it causes a significant decrease in the serum HDL-cholesterol level. OMEE treatment elevates the body, liver and kidney weights significantly. Additionally, it declines the levels of total lipid, triglycerides, and LDL-cholesterol and increase the HDL-cholesterol level significantly. In conclusion, these findings may exhibit a positive hypolipidemic potential of OMEE against dyslipidemia induced by CDDP and suggest that OMEE might serve as novel adjuvant therapy that can be used with CDDP.

Download PDF: